JP2020512284A - 免疫系調節組成物および方法 - Google Patents

免疫系調節組成物および方法 Download PDF

Info

Publication number
JP2020512284A
JP2020512284A JP2019530043A JP2019530043A JP2020512284A JP 2020512284 A JP2020512284 A JP 2020512284A JP 2019530043 A JP2019530043 A JP 2019530043A JP 2019530043 A JP2019530043 A JP 2019530043A JP 2020512284 A JP2020512284 A JP 2020512284A
Authority
JP
Japan
Prior art keywords
domain
intracellular signaling
signaling domain
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512284A5 (enrdf_load_stackoverflow
Inventor
キンバリー エイ ヌーナン
キンバリー エイ ヌーナン
エリック アール ルッツ
エリック アール ルッツ
イヴァン ボレロ
イヴァン ボレロ
Original Assignee
ウィンドミル セラピューティクス インコーポレイテッド
ウィンドミル セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィンドミル セラピューティクス インコーポレイテッド, ウィンドミル セラピューティクス インコーポレイテッド filed Critical ウィンドミル セラピューティクス インコーポレイテッド
Publication of JP2020512284A publication Critical patent/JP2020512284A/ja
Publication of JP2020512284A5 publication Critical patent/JP2020512284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2019530043A 2016-12-22 2017-12-21 免疫系調節組成物および方法 Pending JP2020512284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438106P 2016-12-22 2016-12-22
US62/438,106 2016-12-22
PCT/US2017/067830 WO2018119198A1 (en) 2016-12-22 2017-12-21 Compositions and methods for modulating the immune system

Publications (2)

Publication Number Publication Date
JP2020512284A true JP2020512284A (ja) 2020-04-23
JP2020512284A5 JP2020512284A5 (enrdf_load_stackoverflow) 2021-02-04

Family

ID=62627209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530043A Pending JP2020512284A (ja) 2016-12-22 2017-12-21 免疫系調節組成物および方法

Country Status (10)

Country Link
US (1) US20190330306A1 (enrdf_load_stackoverflow)
EP (1) EP3525805A4 (enrdf_load_stackoverflow)
JP (1) JP2020512284A (enrdf_load_stackoverflow)
KR (1) KR20190096969A (enrdf_load_stackoverflow)
CN (1) CN110267666A (enrdf_load_stackoverflow)
AU (1) AU2017382243A1 (enrdf_load_stackoverflow)
CA (1) CA3038150A1 (enrdf_load_stackoverflow)
IL (1) IL266386A (enrdf_load_stackoverflow)
MX (1) MX2019006852A (enrdf_load_stackoverflow)
WO (1) WO2018119198A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170067751A (ko) * 2014-09-04 2017-06-16 더 존스 홉킨스 유니버시티 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
WO2020236964A1 (en) * 2019-05-20 2020-11-26 The Trustees Of The University Of Pennsylvania Engineered expression of cell surface and secreted sialidase by car t cells for increased efficacy in solid tumors
WO2022211376A1 (ko) * 2021-04-01 2022-10-06 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220144000A (ko) * 2021-04-16 2022-10-26 주식회사 이뮤노로지컬디자이닝랩 Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
EP4334331A1 (en) * 2021-05-07 2024-03-13 Medigene Immunotherapies GmbH Combination of prame specific t cell receptors and chimeric co-stimulatory receptors
WO2025056659A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V AND G12C

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153315A (zh) * 2015-10-09 2015-12-16 重庆倍思益生物科技有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
WO2016037054A1 (en) * 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2017004150A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric antigen receptors therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2723181T3 (es) * 2011-07-29 2019-08-22 Univ Pennsylvania Receptores de conmutación coestimulante
UY35340A (es) * 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3660042B1 (en) * 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016090034A2 (en) * 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
BR112017013177A2 (pt) * 2014-12-19 2018-05-15 Dana Farber Cancer Inst Inc receptores de antígeno quiméricos de anidrase carbônica ix e métodos de uso dos mesmos
MX383164B (es) * 2015-04-22 2025-03-13 CureVac SE Composicion que contiene arn para tratamiento de enfermedades tumorales.
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037054A1 (en) * 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2017004150A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric antigen receptors therapy
JP2018520679A (ja) * 2015-06-29 2018-08-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 免疫チェックポイントキメラ抗原受容体療法
CN105153315A (zh) * 2015-10-09 2015-12-16 重庆倍思益生物科技有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORRELLO, I ET AL: "Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy", FRONTIERS IN IMMUNOLOGY, vol. 7（112）, JPN6021048333, 30 March 2016 (2016-03-30), pages 1 - 7, XP002779629, ISSN: 0004805943, DOI: 10.3389/fimmu.2016.00112 *
LIU, X ET AL: "A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in A", CANCER RESEARCH, vol. 76（６）, JPN6021048337, 15 March 2016 (2016-03-15), pages 1578 - 1590, ISSN: 0004805940 *
NOONAN, K ET AL: "Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity", SCI TRANL MED, vol. 7（288）, JPN6021048332, 2015, pages 1 - 25, ISSN: 0004805944 *
SHIRASU, N ET AL: "Construction and Molecular Characterization of Human Chimeric T-Cell Antigen Receptors Specific for", ANTICANCER RESEARCH, vol. 30, JPN6021048334, 2010, pages 2731 - 2738, XP055658755, ISSN: 0004805942 *
TANG, X ET AL: "The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1+ cancer", AM J TRANSL RES, vol. 7（３）, JPN6021048335, 2015, pages 460 - 473, XP055497234, ISSN: 0004805941 *

Also Published As

Publication number Publication date
EP3525805A1 (en) 2019-08-21
CA3038150A1 (en) 2018-06-28
AU2017382243A1 (en) 2019-05-02
MX2019006852A (es) 2019-08-26
KR20190096969A (ko) 2019-08-20
US20190330306A1 (en) 2019-10-31
WO2018119198A1 (en) 2018-06-28
IL266386A (en) 2019-06-30
EP3525805A4 (en) 2020-07-29
CN110267666A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
JP7527049B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2020512284A (ja) 免疫系調節組成物および方法
JP2024040376A (ja) Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
ES2905557T3 (es) Receptor de antígeno quimérico anti-CD30 y su uso
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP2018520679A (ja) 免疫チェックポイントキメラ抗原受容体療法
CN107523547A (zh) 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
KR20210021593A (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
JP2024514974A (ja) Ａｄｇｒｅ２及び／またはｃｌｅｃ１２ａを標的とするキメラ受容体及びその使用
AU2021209950A1 (en) Quantitative control of activity of engineered cells expressing universal immune receptors
US20220090132A1 (en) Car t cell methods and constructs
US20230058774A1 (en) Novel dominant negative fas polypeptides, cells comprising thereof and uses thereof
US20240000937A1 (en) Methods and compositions of car-expressing natural killer cells with bispecific antigen-binding molecules as cancer therapeutic agents
HK40013643A (en) Compositions and methods for modulating the immune system
JP2024061712A (ja) 葉酸受容体１に特異的なキメラ抗原受容体
CN115340610A (zh) 双特异性car t细胞及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220622